⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 2, 2025Open Access

Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Evan J. Lipson Sonia Dolfi Hao Tang Hussein A. Tawbi Francisco Medina-Soto Erika Castillo Gutiérrez Piotr Rutkowski Helen Gogas E. de Eusebio Murillo Paolo A. Ascierto Keyur Desai Michele Maio Korey Demers Antonella Mazzei Sarah Keidel Karen Miller-Moslin Jia Xin Yu F. Stephen Hodi Dirk Schadendorf Georgina V. Long Charlie Garnett‐Benson

View Full Paper

Ask AI

Bookmark

Share

Key Points

Findings reveal that lag-3+cd8+ subgroups are present in both treatment arms, highlighting potential immune responses.
Prevalence data indicates a distinct distribution of lag-3+cd8+ among patients undergoing different treatments.
Analysis utilized biomarkers to assess T-cell subsets in relation to relatlimab and nivolumab therapies.
Understanding these subgroup dynamics may inform future therapeutic strategies for advanced melanoma cases.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Prevalence of LAG-3+CD8+ subgroups in the NIVO + RELA and NIVO arms.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lipson et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f5ab https://doi.org/10.1158/1078-0432.30029458

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
2Supplementary Figure S7 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
3Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
4Supplementary Figure S8 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
5Supplementary Figure S5 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025

Supplementary Figure S2 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
Supplementary Figure S1 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025
Data from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-0472025